ID   OCI-M2
AC   CVCL_2150
SY   OCI M2; OCIM2
DR   BTO; BTO:0004623
DR   EFO; EFO_0006713
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473109
DR   cancercelllines; CVCL_2150
DR   Cell_Model_Passport; SIDM01841
DR   Cosmic; 787472
DR   Cosmic; 924044
DR   Cosmic; 975294
DR   Cosmic; 1012112
DR   Cosmic; 1245830
DR   Cosmic; 1281349
DR   Cosmic; 1465962
DR   Cosmic; 2306236
DR   Cosmic; 2750870
DR   DepMap; ACH-001618
DR   DSMZ; ACC-619
DR   DSMZCellDive; ACC-619
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM1374792
DR   GEO; GSM1446760
DR   IARC_TP53; 347
DR   PharmacoDB; OCIM2_1191_2019
DR   Wikidata; Q54931783
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3166384;
RX   PubMed=16408098;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=31160637;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Doubling time: ~36 hours (DSMZ=ACC-619).
CC   HLA typing: A*02:01,02:01; B*08:01,44:02; C*05:01,07:06 (PubMed=26589293).
CC   HLA typing: A*02:01:01,02:01:01; B*08:01:01,44:02:01; C*05:01:01,07:01:01 (DSMZCellDive=ACC-619).
CC   Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1268; TSPEAR; Name(s)=RUNX1-TSPEAR (PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Asp (c.821T>A); ClinVar=VCV000376675; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): DepMap; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,14
ST   D16S539: 11
ST   D18S51: 16,20
ST   D19S433: 14
ST   D21S11: 29
ST   D2S1338: 18,24
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 8,11
ST   D8S1179: 10,13
ST   FGA: 21
ST   Penta D: 9 (DSMZ; PubMed=25877200)
ST   Penta D: 9,12 (DepMap)
ST   Penta E: 10,12
ST   TH01: 8,9
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3166384; DOI=10.1182/blood.V72.3.1029.1029;
RA   Papayannopoulou T., Nakamoto B., Kurachi S., Tweeddale M.E.,
RA   Messner H.A.;
RT   "Surface antigenic profile and globin phenotype of two new human
RT   erythroleukemia lines: characterization and interpretations.";
RL   Blood 72:1029-1038(1988).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//